V-VCD Study (AMaRC 18-01)

An exploratory study of Venetoclax in combination with Bortezomib-Cyclophosphamide-Dexamethasone (VCD) induction therapy in newly diagnosed transplant eligible (NDTE MM) multiple myeloma with proteomic correlative studies.

The primary aim of this trial is to determine the rate of complete response achieved by using Venetoclax and VCD.

For more information please visit http://www.amarconline.org/clinical-trials/v-vcd-for-transplant-eligible-myeloma

Project Information

Institution:

Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)

Specialities:

Haematology

Oncology

Other (specify below)

End date:

Suitability:

Parts of research done:

Literature review, Research proposal, Ethics approval

Positions Available:

Data Collector

Statistician

Current Funding:

Abbvie

Website

  • Twitter

Contact

Andrew Spencer

Please fill out the form below to express your interest in this research project. It is free to contact a project owner and express interest in a project. We recommend writing a detailed message regarding why you are interested in the project (e.g. what skills you can bring to the team) or what information you are seeking (e.g. detail regarding the study duration). All information you provide will be shared with the primary researcher, including your contact details. Thank you for your interest in this project.

LINKS:

ABOUT:

Melbourne,

VIC. 3002

Australia

 

0424 730 627

info@theresearchcollab.com

ABN: 77 640 321 295

CONNECT WITH US:

  • Twitter
  • White Facebook Icon
  • White Instagram Icon
  • LinkedIn - White Circle